Floatz logo

PERFLUTREN

Lung Infection

Thunder Bay Regional Health Research InstituteSmall moleculeEarly Phase 1Dormant
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
24/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Lung Infection cohort.

Asset / SponsorPhaseRating
Linezolid
University Ghent
Phase 4BB
Ap-Pa02
Armata Pharmaceuticals, Inc.
Phase 2BB
(±)-1-BUTYL-2',6'-PIPECOLOXYLIDIDE MONOHYDROCHLORIDE
Denver Health and Hospital Authority
Phase 4BB
Amikacin
Asian Institute of Gastroenterology, India
Phase 4BB
Aztreonam Lysine
Gilead Sciences
Phase 3BB

View all 26 →

Same molecule, other indications

PERFLUTREN is also rated in:

Recurrent Renal Cell CarcinomaDormant
B
Indicative ·
60 / 100
View asset →
asthmaDormant
B
Indicative ·
60 / 100
View asset →
Kidney CancerDormant
B
Indicative ·
57 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →